• Home
  • About Us
  • Training Modules
  • Resources
  • Useful Links
  • Blog
  • English
    • Français
Welcome to our Online Training

The Prostate Cancer Training Program will provide you
with important information regarding the pathophysiology,
epidemiology, diagnosis, and treatment of prostate cancer.
It consists of the following 4 modules:

  • Module 1: Prostate Cancer
  • Module 2: Screening, Diagnosis, and Classification
  • Module 3: Castration Resistant Prostate Cancer (CRPC)
  • Module 4: The Role of the Nurse in the Management of Metastatic CRPC

A certificate of completion will be issued once all four modules are completed.
To begin a training module, please provide your name and email before starting:

Select the module you would like to view:
Module 1
Module 2
Module 3
Module 4
Module 1: Prostate Cancer
Duration: 12min 30sec

Learning objectives:

  • Provide key statistics on the burden and impact of prostate cancer
  • Identify risk factors for prostate cancer
  • Describe the mechanism of androgen production
  • Explain the natural history of prostate cancer
  • Determine the role of each member of the multidisciplinary team
    managing patients with prostate cancer
Module 2: Screening, Diagnosis, and Classification
Duration: 11min 45sec

Learning objectives:

  • Determine the role of prostate-specific antigen (PSA) testing and the digital rectal examination (DRE) in the early detection of prostate cancer
  • Understand the CUA recommendations for prostate cancer screening
  • Describe the diagnostic work-up for a patient with suspected prostate cancer
  • List factors used for staging prostate cancer
Module 3: Castration Resistant Prostate Cancer(CRPC)
Duration: 18min 45 sec

Learning objectives:

  • Identify treatment options for early diagnosed nonmetastatic prostate cancer
  • Distinguish different forms of hormonal therapy
  • Describe the CUA recommendations for the management of CRPC (metastatic and non-metastatic)
  • List the goals of treatment in CRPC
  • Describe the CUA recommendations for early detection of metastases
  • Discuss the efficacy of treatments for metastatic CRPC (mCRPC) to improve quality of life
Module 4: Nursing Implication in men with Castration Resistant Prostate Cancer (CRPC)
Duration: 33min 58 sec

Learning objectives:

  • Define the role of the prostate cancer nurse
  • Identify and manage side effects of Androgen Deprivation Therapy (ADT)
  • Identify key diet and exercise strategies to promote wellness
  • Recall key nursing considerations with the different treatment options
  • Understand key tools required to enhance and support survivorship among prostate cancer patients
Start Module
Take the quiz
View/Print Certificate

  1. What is the major function of the prostate?
    1 of 9
  2. Where do the majority of prostate cancers begin?
    2 of 9
  3. Select the patient with the highest risk of developing prostate cancer
    3 of 9
  4. What effect do androgens have on prostate cells?
    4 of 9
  5. What are the most common sites of prostate cancer metastasis?
    5 of 9
  6. In 2014, approximately what percentage of all cancer death where from prostate cancer?
    6 of 9
  7. Between 2001 and 2009, the death rate from prostate cancer:
    7 of 9
  8. Which of the following specialists analyzes the prostate biopsy?
    8 of 9
  9. Which of the following specialists delivers potentially curative or palliative radiation therapy?
    9 of 9
  1. What DRE findings are suggestive of prostate cancer?
    1 of 10
  2. DRE alone approximately misses what percentage of prostate cancers?
    2 of 10
  3. Which of the following can affect PSA values?
    3 of 10
  4. How many PSA measurements must be used to calculate PSA doubling time?
    4 of 10
  5. Which of the following is a CUA recommendation for prostate cancer screening?
    5 of 10
  6. Which of these components of the diagnostic work-up can provide a definite diagnosis of prostate cancer
    6 of 10
  7. Which of the following statements is TRUE regarding bone scans?
    7 of 10
  8. Which of these factors are used in prostate cancer classification?
    8 of 10
  9. Which of the following Gleason scores are considered high-grade?
    9 of 10
  10. Which of these factors are used to determine prostate cancer staging?
    10 of 10
  1. Which of the following is a NOT a common treatment option for nonmetastatic prostate cancer?
    1 of 9
  2. During active surveillance, how are patients usually monitored?
    2 of 9
  3. Which of the following statements is TRUE regarding radical prostatectomy?
    3 of 9
  4. Which of the following statements is TRUE regarding LHRH agonists and antagonists?
    4 of 9
  5. Which of the following treatments is recommended for symptomatic mCRPC patients?
    5 of 9
  6. In which prostate cancer setting is cabazitaxel recommended?
    6 of 9
  7. Which of the following treatments are recommended for mCRPC patients with minimal or no symptoms?
    7 of 9
  8. How often should a patient with slow PSA doubling time be monitored for metastases?
    8 of 9
  9. Which of the following treatment options achieved a 10 months delay in time to opiate use :
    9 of 9
  1. What is the best way to combat fatigue in men undergoing ADT?
    1 of 10
  2. What are the symptoms of a hot flash?
    2 of 10
  3. What is NOT a tip to manage a hot flash
    3 of 10
  4. What are the related side effects of ADT?
    4 of 10
  5. 5. Men on ADT have an increased risk of developing osteoporosis or osteopenia because
    5 of 10
  6. What is the usual calcium dosage for men on hormone therapy?
    6 of 10
  7. What are the potential body changes associated with ADT?
    7 of 10
  8. What is a potential treatment of chronic urinary retention?
    8 of 10
  9. What are the signs of CRPC?
    9 of 10
  10. Abiraterone Acetate is reimbursed and approved by health Canada:
    10 of 10

Congratulations, you have completed The Prostate Cancer Training Program. You may now view and print your certificate of completion.

Sponsored by Janssen / Amgen
  • About CUA
  • Terms of Use
  • Contact Us
  • English
    • Français

This web site is provided as a convenience to you and is for informational purposes only. The information on or available through this web site is not a substitute for professional medical care by a qualified doctor or other health care professional.

For comments or information, e-mail corporate.office@cua.org

Share our website

Coming soon